<DOC>
	<DOCNO>NCT00791804</DOCNO>
	<brief_summary>To evaluate safety efficacy self-titration effective analgesia inhale AeroLEF patient moderate/severe acute pain post-surgical setting .</brief_summary>
	<brief_title>Phase II Study Inhaled AeroLEF Analgesia After ACL Knee Surgery</brief_title>
	<detailed_description>After elective ACL knee surgery , consent patient receive single dose AeroLEF moderate/severe acute pain . Patients stop dose achieve analgesia , complete maximum available dose , experience dose-limiting side effect .</detailed_description>
	<mesh_term>Pain , Postoperative</mesh_term>
	<mesh_term>Fentanyl</mesh_term>
	<criteria>1 . Male female age 18 year 60 year . 2 . A body mass index 18 30 , inclusive . 3 . If female childbearing potential , patient must negative urine pregnancy test screen baseline . 4 . Scheduled elective ACL arthroscopic knee repair surgery , meet criterion American Society Anesthesiologists [ ASA ] Physical Status Criteria Class I Class II , suitability anesthetic plan limit general anesthesia ( inhalation/IV ) postoperative PCA initiate PACU set require CPM 12 hour post surgery observation complete . 5 . Scheduled morning surgery anticipate remain hospital overnight stay . 6 . Normal laboratory value clinical chemistry , haematology urinalysis . If patient abnormal clinically significant laboratory value , inclusion permit discretion investigator . 7 . Physical examination clinically relevant finding determine investigator . 8 . Able demonstrate ability understand requirement study , willingness provide write informed consent ( prior studyrelated procedure perform ) able adhere study restriction , return require assessment . 1 . History addiction drug alcohol . 2 . Exposure investigational drug within 30 day prior enrolment . 3 . Documented hypersensitivity fentanyl opioid analgesic 4 . Documented hypersensitivity/allergy component liposome use AeroLEF formulation 5 . History pulmonary , cardiovascular , neurologic , endocrine , hepatic , GI , kidney disease therapy would jeopardize patient 's wellbeing participation study ( excluded ASA I II category ) 6 . Currently receive treatment , receive treatment previous two week , antidepressant antipsychotic drug ( include monoamine oxidase inhibitor ) . 7 . Clinically significant ongoing medical condition . 8 . Currently receive treatment chronic pain . 9 . Current therapy narcotic CNSdepressant medication . 10 . Current chronic therapy NSAIDs , ASA acetaminophen within previous 7 day . 11 . Patient , opinion investigator , mentally emotionally unsuitable participate , unable/unwilling comply study assessment . 12 . Blood donation blood loss within 45 day prior enrolment study total 100 mL great .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>60 Years</maximum_age>
	<verification_date>November 2008</verification_date>
	<keyword>Pain</keyword>
	<keyword>Post Op pain</keyword>
	<keyword>Fentanyl</keyword>
	<keyword>Pain Control</keyword>
	<keyword>Surgery</keyword>
</DOC>